Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.

Bittner, Stefan; Steffen, Falk; Uphaus, Timo; Muthuraman, Muthuraman; Fleischer, Vinzenz; Salmen, Anke; Luessi, Felix; Berthele, Achim; Klotz, Luisa; Meuth, Sven G; Bayas, Antonios; Paul, Friedemann; Hartung, Hans-Peter; Linker, Ralf; Heesen, Christoph; Stangel, Martin; Wildemann, Brigitte; Then Bergh, Florian; Tackenberg, Björn; Kuempfel, Tania; ... (2020). Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine, 56, p. 102807. Elsevier 10.1016/j.ebiom.2020.102807

[img]
Preview
Text
Bittner, 2020, Clinical implications of serum neurofilament.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (3MB) | Preview

BACKGROUND

We aim to evaluate serum neurofilament light chain (sNfL), indicating neuroaxonal damage, as a biomarker at diagnosis in a large cohort of early multiple sclerosis (MS) patients.

METHODS

In a multicentre prospective longitudinal observational cohort, patients with newly diagnosed relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) were recruited between August 2010 and November 2015 in 22 centers. Clinical parameters, MRI, and sNfL levels (measured by single molecule array) were assessed at baseline and up to four-year follow-up.

FINDINGS

Of 814 patients, 54.7% (445) were diagnosed with RRMS and 45.3% (369) with CIS when applying 2010 McDonald criteria (RRMS[2010] and CIS[2010]). After reclassification of CIS[2010] patients with existing CSF analysis, according to 2017 criteria, sNfL levels were lower in CIS[2017] than RRMS[2017] patients (9.1 pg/ml, IQR 6.2-13.7 pg/ml, n = 45; 10.8 pg/ml, IQR 7.4-20.1 pg/ml, n = 213; p = 0.036). sNfL levels correlated with number of T2 and Gd+ lesions at baseline and future clinical relapses. Patients receiving disease-modifying therapy (DMT) during the first four years had higher baseline sNfL levels than DMT-naïve patients (11.8 pg/ml, IQR 7.5-20.7 pg/ml, n = 726; 9.7 pg/ml, IQR 6.4-15.3 pg/ml, n = 88). Therapy escalation decisions within this period were reflected by longitudinal changes in sNfL levels.

INTERPRETATION

Assessment of sNfL increases diagnostic accuracy, is associated with disease course prognosis and may, particularly when measured longitudinally, facilitate therapeutic decisions.

FUNDING

Supported the German Federal Ministry for Education and Research, the German Research Council, and Hertie-Stiftung.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Salmen, Anke

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2352-3964

Publisher:

Elsevier

Language:

English

Submitter:

Chantal Kottler

Date Deposited:

05 Nov 2020 17:03

Last Modified:

13 Mar 2021 11:51

Publisher DOI:

10.1016/j.ebiom.2020.102807

PubMed ID:

32460167

Uncontrolled Keywords:

Biomarker Multiple sclerosis Neurofilament light chain Prediction sNfL

BORIS DOI:

10.7892/boris.147347

URI:

https://boris.unibe.ch/id/eprint/147347

Actions (login required)

Edit item Edit item
Provide Feedback